Smokeless tobacco topography and toxin exposure.
暂无分享,去创建一个
D. Hatsukami | S. Hecht | S. Murphy | Yan Zhang | S. Carmella | J. Jensen | C. Lemmonds | Joni A. Jensen | S. Hecht
[1] B. Grant,et al. Patterns of DSM-IV alcohol abuse and dependence criteria among adolescents and adults: results from the 2001 National Household Survey on Drug Abuse. , 2005, Alcoholism, clinical and experimental research.
[2] Laura Kann,et al. Youth risk behavior surveillance--United States, 2003. , 2004, Morbidity and mortality weekly report. Surveillance summaries.
[3] Connie Lim,et al. Youth Risk Behavior Surveillance--United States, 2009. Morbidity and Mortality Weekly Report. Surveillance Summaries. Volume 59, Number SS-5. , 2004 .
[4] Dorothy K Hatsukami,et al. Smokeless tobacco use: harm reduction or induction approach? , 2004, Preventive medicine.
[5] D. Hatsukami,et al. Situational factors and patterns associated with smokeless tobacco use , 1991, Journal of Behavioral Medicine.
[6] D. Hatsukami,et al. Topographical features of smokeless tobacco use , 1988, Psychopharmacology.
[7] S. Hecht,et al. Analysis of total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in human urine. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[8] D. Hatsukami,et al. Preliminary study on reducing oral moist snuff use. , 2003, Drug and alcohol dependence.
[9] E. Weiderpass,et al. Smokeless tobacco: harm reduction or nicotine overload? , 2003, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.
[10] S. Hecht,et al. Human urinary carcinogen metabolites: biomarkers for investigating tobacco and cancer. , 2002, Carcinogenesis.
[11] D. Hatsukami,et al. Quantitation of metabolites of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone after cessation of smokeless tobacco use. , 2002, Cancer research.
[12] D. Hatsukami,et al. Quantitation of urinary metabolites of a tobacco-specific lung carcinogen after smoking cessation. , 1999, Cancer research.
[13] S. Hecht,et al. Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. , 1998, Chemical research in toxicology.
[14] Tobacco,et al. Nicotine safety and toxicity , 1998 .
[15] S. Hecht,et al. Metabolites of a tobacco-specific nitrosamine, 4-(methylnitrosamino)- 1-(3-pyridyl)-1-butanone (NNK), in the urine of smokeless tobacco users: relationship between urinary biomarkers and oral leukoplakia. , 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[16] G. Connolly,et al. Five leading U.S. commercial brands of moist snuff in 1994: assessment of carcinogenic N-nitrosamines. , 1995, Journal of the National Cancer Institute.
[17] V. Stevens,et al. The inside scoop on the stuff called snuff: an interview study of 94 adult male smokeless tobacco users. , 1990, Journal of substance abuse.
[18] D Hoffmann,et al. The relevance of tobacco-specific nitrosamines to human cancer. , 1989, Cancer surveys.
[19] S. Hecht,et al. Tobacco-specific nitrosamines, an important group of carcinogens in tobacco and tobacco smoke. , 1988, Carcinogenesis.
[20] D. Hatsukami,et al. Physiologic and subjective changes from smokeless tobacco withdrawal , 1987, Clinical pharmacology and therapeutics.
[21] W. Blot,et al. Health consequences of using smokeless tobacco: summary of the Advisory Committee's report to the Surgeon General. , 1986, Public health reports.
[22] Tobacco habits other than smoking; betel-quid and areca-nut chewing; and some related nitrosamines. IARC Working Group. Lyon, 23-30 October 1984. , 1985, IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans.
[23] P. Udani,et al. Morbidity and mortality. , 1962, The Indian journal of child health.